Biotheranostics, Inc. has announced new pivotal data on the Breast Cancer Index (BCI) being presented at the ASCO conference June 3, 2019 that further validates its ability to accurately predict which women with early-stage, hormone receptor positive (HR+) breast cancer will benefit from extended endocrine therapy. Findings from the Translational-aTTom study (Trans-aTTom) led by an international team of cancer researchers strengthen BCI clinical evidence as a predictive biomarker and highlight its utility in helping physicians determine 5 vs. 10-year endocrine treatment plans for their patients.

The Trans-aTTom study to date includes 1,822 patients treated in the aTTom trial, which randomized nearly 7,000 HR+ women to either stop or continue tamoxifen for 5 more years after completing at least 4 years of endocrine therapy. Data presented on 583 patients with N+ disease demonstrated that the Breast Cancer Index effectively stratified patients based on their response to extended endocrine therapy, identifying 49% of patients that showed a statistically significant benefit of 10.2% with 10 years of tamoxifen, and 51% of patients that did not show a statistically significant benefit from continued treatment. These data provide further validation and establish level 1B evidence for Breast Cancer Index as the only predictive biomarker for benefit from extended endocrine therapy in early-stage, HR+ breast cancer.

A significant dilemma in early-stage, HR+ breast cancer is determining the optimal duration of endocrine therapy to reduce the ongoing risk of distant recurrence. For breast cancer patients on endocrine therapy, the side effects and toxicities associated with treatment often have a severe impact on health and quality of life (e.g., osteoporosis, endometrial cancer, blood clots, joint pain) For these women, weighing the health risks against the potential benefit of continuing endocrine therapy beyond 5 years is essential for individual treatment planning. Thus, identifying women for whom extending endocrine therapy helps reduce their risk of recurrence is important to help decrease their anxiety, increase their satisfaction and comfort with their treatment decision, and potentially enable them to comply effectively with their treatment plan. Breast Cancer Index is the only test validated to predict which patients will benefit from endocrine therapy beyond 5 years, helping inform the decision of 5 vs 10 years of endocrine therapy. No other genomic tests or clinicopathologic factors have demonstrated the ability to predict extended endocrine therapy benefit.

Catherine Schnabel, Ph.D., Chief Scientific Officer, Biotheranostics, said, “Results from the Trans-aTTom study add to the growing body of evidence that BCI accurately identifies which early-stage HR+ patients are associated with better outcomes and preferential response to extended endocrine therapy. Clinicians may use BCI to personalize their approach and provide validated genomic information to help patients weigh the risks and benefits of prolonging their endocrine treatment.”

Don Hardison, Biotheranostics’ President, and CEO added, “We are very pleased with results from the Trans-aTTom validation study. It provides further validation that Breast Cancer Index is the only predictive biomarker for extended endocrine therapy in early-stage, HR+ breast cancer. We are committed to ensuring that every breast cancer patient and her physician have information to help determine the best approach to individualize treatment.”

Latest news

OSSIO Launches World’s First and Only Non-Permanent Compression Staple
February 7, 2023

OSSIOfiber® Compression Staple Answers Surgeon, Patient Demand in Fastest Growing Product Category in Extremities WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation […]

VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
February 6, 2023

Second Generation GENOSYL® DS is the first and only Inhaled Nitric Oxide delivery system that is FDA-approved for rebreathing anesthesia, […]

VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
January 9, 2023

VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced […]

MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022

BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]

MVM Invests in Ossio
October 18, 2022

Proceeds will be used to strengthen awareness for the patient benefits of bio-integrative OSSIOfiber® implants and accelerate new product platforms into the major […]

MVM invests in Neurolens
September 12, 2022

Neurolens, a company commercializing innovative solutions to optimize vision, today announced completion of a $67 million financing. The financing was led by […]

MDxHealth acquires Oncotype DX GPS test
August 2, 2022

MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced it has entered into an […]

Nalu announces new CEO
July 14, 2022

Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today […]

MVM invests in Nalu Medical
February 17, 2022

CARLSBAD, Calif. (PRWEB) February 17, 2022 Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]

Clarivate acquires Patient Connect
December 22, 2021

 Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]